Clorox's disinfecting wipes won't be fully available in groceries until next year, with stocks running low due to the six-fold increase in demand, says CEO Benno Dorer.
According to Dorer, other than being the hottest commodity in its product line, disinfecting wipes take longer to produce because of a very complex supply chain.
He noted that wipes are made from polyester spunlace, which are currently in short supply as it is also a material for protective wear like masks and medical gowns.
However, supply for most of Clorox's products, like liquid bleach, will improve dramatically over the next four to six months.
Since the start of global lockdowns, hygiene goods makers have a sustained boom in sales.
The California-based company has a stock shortage across much of its products, such as Burt's Bees lip balm and Glad trash bags.
While Clorox usually holds excess supply for flu seasons, it cannot keep up with overwhelming pandemic-triggered demand for many of its disinfectants.
Dorer said the entire supply chain is stressed and that it would probably take the company until 2021 to meet the demand.


TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 



